A greater proportion of patients treated with dapagliflozin had a clinically meaningful improvement of ≥ 5 points in KCCQ-OS or at least a 20% reduction in NT-proBNP, as compared with placebo (61.5% vs. 50.4%, adjusted OR 1.8; 95% CI, 1.03 to 3.06, P = 0.039), the results were consistent within subgroups of patients with and without T2D [20]. This evidence concerns the gene NPPB and type 2 diabetes mellitus.